Emergence of ad-mediated combination therapy against cancer: What to expect?

Jin Woo Hong, Chae Ok Yun

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancer-specific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.

Original languageEnglish
Pages (from-to)139-152
Number of pages14
JournalCurrent Cancer Drug Targets
Volume18
Issue number2
DOIs
StatePublished - 2018 Jan 1

Fingerprint

Adenoviridae
Neoplasms
Therapeutics
Virion
Immunotherapy
Radiotherapy
Clinical Trials
Drug Therapy
Genes

Keywords

  • Adenovirus
  • Cancer
  • Chemotherapy
  • Combination therapy
  • Immunotherapy
  • Oncolytic adenovirus
  • Radiotherapy

Cite this

@article{fd7ea636e71a47028a645bbb316a876f,
title = "Emergence of ad-mediated combination therapy against cancer: What to expect?",
abstract = "Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancer-specific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.",
keywords = "Adenovirus, Cancer, Chemotherapy, Combination therapy, Immunotherapy, Oncolytic adenovirus, Radiotherapy",
author = "Hong, {Jin Woo} and Yun, {Chae Ok}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1568009617666170222123406",
language = "English",
volume = "18",
pages = "139--152",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
number = "2",

}

Emergence of ad-mediated combination therapy against cancer : What to expect? / Hong, Jin Woo; Yun, Chae Ok.

In: Current Cancer Drug Targets, Vol. 18, No. 2, 01.01.2018, p. 139-152.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emergence of ad-mediated combination therapy against cancer

T2 - What to expect?

AU - Hong, Jin Woo

AU - Yun, Chae Ok

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancer-specific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.

AB - Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancer-specific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.

KW - Adenovirus

KW - Cancer

KW - Chemotherapy

KW - Combination therapy

KW - Immunotherapy

KW - Oncolytic adenovirus

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85042144574&partnerID=8YFLogxK

U2 - 10.2174/1568009617666170222123406

DO - 10.2174/1568009617666170222123406

M3 - Review article

C2 - 28228085

AN - SCOPUS:85042144574

VL - 18

SP - 139

EP - 152

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 2

ER -